Biocon wins EU approval for first tailored-pathway biosimilar
Key highlights
- Biocon received European Commission authorisation for 420 mg Pebrilzo on November 18, 2026.
- Pebrilzo is the first biosimilar approved under the EMA’s tailored clinical approach.
- The EU decision followed a positive CHMP opinion issued on September 17, 2026.
- Pertuzumab is Biocon’s fifth oncology biosimilar approved in both Europe and the United States.
powered by IRIS

Biocon Limited received European Union marketing authorisation on November 18, 2026, for 420 mg Pebrilzo, its pertuzumab biosimilar for HER2-positive breast cancer, making it the first biosimilar approved under the European Medicines Agency’s tailored clinical approach. The decision follows a positive opinion issued on September 17, 2026.
Know Biocon inside out
Results, valuation, peers and who's buying, in one view.
What did Biocon receive EU approval for?
Biocon received European Commission marketing authorisation for Pebrilzo, a 420 mg concentrate for solution for infusion, across multiple HER2-positive breast-cancer stages in the European Union. Pebrilzo is a biosimilar medicinal product whose active substance is pertuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2, or HER2.
The November 18, 2026 decision followed a positive opinion from the Committee for Medicinal Products for Human Use, or CHMP, on September 17, 2026. The progression from CHMP opinion to European Commission approval took about two months and gives Biocon an authorised pertuzumab biosimilar in the EU.
Biocon said pertuzumab binds with high affinity and specificity to HER2 and inhibits proliferation of tumour cells that overexpress the receptor. The announcement also said the EU authorisation follows a recent approval by the U.S. Food and Drug Administration, although it did not give a date for that decision.
Why is Pebrilzo the first biosimilar on this pathway?
Pebrilzo is the first biosimilar to receive European Commission marketing authorisation under the European Medicines Agency’s, or EMA’s, new tailored clinical approach. Biocon identified the regulatory route as the central distinction of the November 2026 approval.
Biocon said its evidence package included extensive orthogonal structural and functional analytical characterisation and comparative clinical pharmacokinetic data. Pharmacokinetics measures how the body handles a medicine, and Biocon said the data demonstrated high similarity to the reference product, with no clinically meaningful differences in quality, safety or efficacy.
The announcement does not provide numerical pharmacokinetic findings or describe comparative efficacy trials for individual authorised uses. It does state that the analytical, functional and pharmacokinetic evidence supported approval of the 420 mg pertuzumab biosimilar through the EMA’s tailored clinical framework.
Which HER2-positive breast cancer settings does Pebrilzo cover?
Pebrilzo is authorised with trastuzumab and chemotherapy for adult patients with HER2-positive locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence in the neoadjuvant setting. Neoadjuvant treatment is treatment given before a main intervention, such as surgery.
The same combination of Pebrilzo, trastuzumab and chemotherapy is authorised for adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence. Adjuvant treatment is given after the main treatment, and the announcement distinguishes this setting from locally advanced and inflammatory disease.
For metastatic or locally recurrent unresectable breast cancer, Pebrilzo is authorised with trastuzumab and docetaxel. This use is for adult patients with HER2-positive disease who have not received previous anti-HER2 treatment or chemotherapy for metastatic disease.
Biocon cited estimates that approximately 15-20% of invasive breast cancers are characterised by HER2 overexpression or amplification. It also cited 2024 European Cancer Information System estimates identifying breast cancer as the leading cancer diagnosis among women in Europe.
Got a follow-up? Ask IRIS
How does the approval change Biocon’s oncology portfolio?
The approval makes pertuzumab Biocon’s fifth oncology biosimilar approved in both Europe and the United States, according to Chief Executive Officer and Managing Director Shreehas Tambe. The count shows that pertuzumab adds to an existing cross-market oncology biosimilar portfolio rather than being Biocon’s first product in the category.
Biocon said its oncology portfolio includes medicines for solid tumours, including breast cancer, and supportive care for chemotherapy-induced neutropenia. It also includes therapies addressing osteoporosis, treatment-related bone loss and skeletal complications associated with advanced cancers, with pertuzumab adding a HER2-targeted option across early and metastatic breast-cancer settings.
Across its broader operations, Biocon said it has commercialised 12 biosimilar products and more than 30 generic formulations globally. The company also disclosed a research and development pipeline of more than 20 biosimilar assets, alongside glucagon-like peptide-1, or GLP-1, peptides and other complex generics.
Biocon operates in more than 120 countries through seven manufacturing sites, three research and development sites and 18 offices, supported by a workforce of more than 9,500 employees. The November 18 announcement does not disclose Pebrilzo revenue expectations, EU sales targets, pricing or country-specific launch dates.
What is known about Pebrilzo’s European availability?
Biocon confirmed EU marketing authorisation for Pebrilzo on November 18, 2026, but did not disclose a commercial launch timetable for individual European countries. The filing therefore establishes the product’s regulatory status without setting out availability dates by market.
The company said the approval aims to broaden treatment options for patients with HER2-positive breast cancer while supporting more sustainable healthcare systems in Europe. However, Biocon did not quantify expected cost savings, treatment uptake, patient numbers or sales volumes for the 420 mg product.
The comparison between the September 17 CHMP opinion and the November 18 Commission decision provides a completed regulatory sequence for Pebrilzo. In contrast, Biocon gave no timetable for the more than 20 biosimilar assets in its research and development pipeline.
Conclusion
The November 18, 2026 European Commission decision gives Biocon an EU-authorised 420 mg pertuzumab biosimilar for specified HER2-positive breast-cancer settings. Pebrilzo is the first biosimilar approved through the EMA’s tailored clinical approach and raises Biocon’s count to five oncology biosimilars approved in both Europe and the United States.
The next disclosed issue to watch is commercial availability across European markets, as Biocon gave no country-level launch, pricing or revenue plan for Pebrilzo. Investors can also watch progress in Biocon’s pipeline of more than 20 biosimilar assets, although the announcement does not provide regulatory dates for those programmes.


